BeiGene's Zanidatamab Regimen Extends Survival in HER2-Positive Gastroesophageal Adenocarcinoma, but Combination Difference Falls Short
Start here
In the Phase 3 HERIZON-GEA-01 trial, BeiGene evaluated zanidatamab plus tislelizumab and chemotherapy as first-line treatment for HER2-positive gastroesophageal adenocarcinoma. The three-drug regimen achieved a median overall survival of 27.0 months. However, the survival difference versus the comparator arm of zanidatamab plus chemotherapy did not reach statistical significance, leaving open the question of how much tislelizumab adds to the backbone. Further details from the trial, including progression-free survival and safety results, have not been reported in the available coverage.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickBeiGene HERIZON-GEA-01: Zanidatamab Plus Tislelizumab and Chemo Extends OS in HER2-Positive Gastroesophageal Adenocarcinoma, Difference Versus Zanidatamab Plus Chemo Not Significant
In the Phase 3 HERIZON-GEA-01 trial from BeiGene, zanidatamab combined with tislelizumab and chemotherapy as first-line treatment for HER2-positive gastroesophageal adenocarcinoma achieved a median overall survival of 27.0 months. The difference versus the zanidatamab plus chemotherapy group did not reach statistical significance.
Heat trend for this story
Heat now 8·Peak in the comparable set 10 (Oct 24 10:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.